Neoplasms

Blood and Lymph Conditions

All Conditions

Hematologic Neoplasms

Hematologic Diseases

Long term follow-up of subjects with solid or hematological malignancies who have received lentivirus-mediated genetically engineered T Cell Receptors in a previous trial

No study drug is administered in this study. Subjects who received lentivirus-mediated genetically engineered T Cell Receptors in a previous trial will be evaluated in this trial for long-term safety and efficacy.

Genetically engineered T Cell Receptors

Marcus Butler, MD

Subjects who previously took part in an Adaptimmune study and received genetically changed T cells (including but not limited to MAGE-A10ᶜ⁷⁹⁶T and MAGE-A4ᶜ¹º³²T) are asked to take part in this long term follow-up study. Subjects will be asked to join this study once they complete the parent interventional study.

The purpose of this study is to find out if the genetically changed T cells that subjects received in the parent study have any long-term side effects. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.

For a period of 15 years starting from last administration of the genetically changed T cells, subjects will visit their study doctor for a check-up and to have blood tests to look for any changes that might have happened because of the genetically changed T cells.

This is a non-therapeutic, multi-center, long-term follow-up (LTFU) study of subjects who have received lentivirus-mediated genetically engineered T Cell Receptors in an Adaptimmune sponsored clinical trial. The study is designed in accordance with FDA and EMA guidance on gene therapy trials.

The study involves up to 15 years post-infusion monitoring of subjects who have been exposed to lentivirus-mediated gene transfer in Adaptimmune clinical studies. The study will include subjects who have received various T cell receptors including but not limited to MAGE-A10ᶜ⁷⁹⁶T and MAGE-A4ᶜ¹º³²T. Subjects will undergo clinical evaluation (i.e., new medical history, physical exam, adverse events, and exposure to mutagenic agents, anti-cancer therapies and investigational products in other clinical studies) with careful attention to adverse events possibly related to gene transfer or lentivirus-induced diseases. Blood samples will be collected for evaluating persistence of cells with lentiviral vector sequences, the detection of replication competent lentivirus (RCL), and chemistry and hematology laboratory assessments. Subjects will be followed for survival.

Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors

Long Term Follow-up of Subjects Exposed to Genetically Engineered Tumor Antigen Specific T Cell Receptors

* New malignancies
* New incidence or exacerbation of a pre-existing neurologic disorder
* New incidence or exacerbation of a prior rheumatologic or other autoimmune disorder
* New incidence of a hematologic disorder
* Opportunistic and/or serious infections
* Unanticipated illness and/or hospitalization deemed related to gene modified cell therapy

Subjects' peripheral blood samples will be used to evaluate RCL

Peripheral blood samples will be used to evaluate persistence

Number of samples positive for vector integration by PCR

OS defined as the interval between the date of first T cell infusion and date of death due to any cause

Adaptimmune

Antineoplastic Agents

All Drugs and Chemicals

Brexucabtagene autoleucel

Axicabtagene ciloleucel

Antineoplastic Agents, Immunological

All participants who previously received axicabtagene ciloleucel (KTE-C19 ) in the parent study will be enrolled in this arm for long-term follow-up.

All participants who previously received brexucabtagene autoleucel (KTE-X19) in the parent study will be enrolled in this arm for long-term follow-up.

All participants who previously received KITE-585 in the parent study will be enrolled in this arm for long-term follow-up.

All participants who previously received KITE-718 in the parent study will be enrolled in this arm for long-term follow-up.

All participants who previously received KITE-439 in the parent study will be enrolled in this arm for long-term follow-up.

All participants who previously received KITE-222 in the parent study will be enrolled in this arm for long-term follow-up.

All participants who previously received KITE-363 in the parent study will be enrolled in this arm for long-term follow-up.

No investigational product will be administered

Axicabtagene Ciloleucel

Brexucabtagene Autoleucel

KITE-585

KITE-718

KITE-439

KITE-222

KITE-363

Kite Study Director

The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-222, KITE-363, KITE-439, KITE-585, and KITE-718, in participants of Kite-sponsored interventional studies.

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Targeted AEs include late-onset targeted AEs suspected to be possibly related to gene-modified cells include neurologic disorders, autoimmune disorders, hematologic disorders, serious infections, and secondary malignancies.

Targeted SAEs include late-onset targeted SAEs suspected to be possibly related to gene-modified cells include neurologic disorders, autoimmune disorders, hematologic disorders, serious infections, and secondary malignancies.

The Tanner Pubertal Stage Scale is a measure of pubertal development (sexual maturation) in children and adolescents with components described for each sex, rated separately on a scale of stage one to stage five, with 1 for preadolescent and 5 for mature/adult.

Time to subsequent anticancer therapies will be assessed only per regulatory request or sponsor needs.

Survival status will be assessed as the length of time from the participant's first dose date of study drug to death during the study due to any cause or last date of being alive during the study. Survival status will be assessed only per regulatory request or sponsor needs.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors	NCT03391791	Solid and Hemat...	Genetically eng...	18 Years -	Adaptimmune
Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors	NCT03391791	Solid and Hemat...	Genetically eng...	18 Years -	Adaptimmune
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells	NCT05041309	Solid and Hemat...	Axicabtagene Ci... Brexucabtagene ... KITE-585 KITE-718 KITE-439 KITE-222 KITE-363	-	Gilead Sciences

Spots Global Cancer Trial Database for solid and hematological malignancies